Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer

Journal of Immunotherapy

Volumn 27, Issue 3, 2004, Pages 240-253

  Pantuck, Allan J ^a   Van Ophoven, Arndt ^a   Gitlitz, Barbara J ^a   Tso, Cho Lea ^a   Acres, Bruce ^b   Squiban, Patrick ^b   Ross, Michael E ^b   Belldegrun, Arie S ^a   Figlin, Robert A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TRANSGENE S A   (France)

Author keywords

Gene therapy; Immunotherapy; Interleukin 2; MUC 1; Prostate cancer

Indexed keywords

BETA ACTIN; CD3 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; MESSENGER RNA; MUCIN 1; PROSTATE SPECIFIC ANTIGEN; T LYMPHOCYTE RECEPTOR; TG 1031; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADVANCED CANCER; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CLONAL ANERGY; CYTOTOXICITY; DIZZINESS; DRUG SAFETY; DYSPNEA; ERYTHEMA; FEVER; FLUORESCENCE ACTIVATED CELL SORTING; GENE OVEREXPRESSION; GENE THERAPY; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERHIDROSIS; HYPERTENSION; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATION; INJECTION SITE; MALAISE; MALE; MAXIMUM TOLERATED DOSE; MUSCLE WEAKNESS; MYALGIA; NONHUMAN; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THORAX PAIN; TUMOR CELL; VACCINIA VIRUS; VIRUS RECOMBINANT;

EID: 4344713204     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200405000-00009     Document Type: Article

References (39)

1. Wingo PA, Cardinez CJ, Landis SH, et al. Long-term trends in cancer mortality in the United States, 1930-1998. Cancer. 2003;97:3133-3275.
2. Kawakami Y, Nishimura MI, Restifo NP, et al. T-cell recognition of human melanoma antigens. J Immunother. 1993;14:88-93.
3. Healy C, Simons J, Carducci M, et al. Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry. 1998;32:109-119.
4. Lloyd KO, Burchell J, Kudryashov V, et al. Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells. J Biol Chem. 1996;271:33325-33334.
5. Hiltbold EM, Alter MD, Ciborowski P, et al. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells. Cell Immunol. 1999;194: 143-149.
6. Barnd DL, Lan MS, Metzgar RS, et al. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA. 1989;86:7159-7163.
7. Belldegrun A, Muul LM, Rosenberg SA. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res. 1988;48:206-214.
8. Chen YM, Yang WK, Whang-Peng J, et al. Restoration of the immunocompetence by IL-2 activation and TCR-CD3 engagement of the in vivo anergized tumor-specific CTL from lung cancer patients. J Immunother. 1997;20:254-264.
9. Belldegrun A, Tso CL, Zisman A, et al. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther. 2001;12:883-892.
10. Scholl SM, Balloul JM, Le Goc G, et al. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother. 2000;23:570-580.
11. Belldegrun A, Tso CL, Kaboo R, et al. Natural immune reactivity- associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy. J Immunother. 1996;19:149-161.
12. von Mensdorff Pouilly S, Gourevitch MM, Kenemans P, et al. An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1). Tumor Biol. 1998;19: 186-195.
13. Scholl S, Squiban P, Bizouarne N, et al. Metastatic breast tumour regression following treatment by a gene-modified vaccinia virus expressing MUC1 and IL-2. J Biomed Biotechnol. 2003;3:194-201.
14. Magarian-Blander J, Ciborowski P, Hsia S, et al. Intercellular and intracellular events following the MHC-unrestricted TCR recognition of a tumor-specific peptide epitope on the epithelial antigen MUC1. J Immunol. 1998;160:3111-3120.
15. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281:1591-1597.
16. Jantscheff P, Herrmann R, Spagnoli GC, et al. Gene therapy with cytokine-transfected xenogenic cells (Vero-IL-2) in patients with metastatic solid tumors: mechanisms of elimination of the transgene-carrying cells. Cancer Immunol Immunother. 1999;48:321-330.
17. Jerome KR, Kirk AD, Pecher G, et al. A survivor of breast cancer with immunity to MUC-1 mucin, and lactational mastitis. Cancer Immunol Immunother. 1997;43:355-360.
18. Apostolopoulos V, Osinski C, McKenzie IF. MUC1 cross-reactive Gal alpha(1,3)Gal antibodies in humans switch immune responses from cellular to humoral. Nat Med. 1998;4:315-320.
19. Musselli C, Ragupathi G, Gilewski T, et al. Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int J Cancer. 2002;97:660-667.
20. Goydos JS, Elder E, Whiteside TL, et al. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res. 1996;63:298-304.
21. Horiguchi S, Petersson M, Nakazawa T, et al. Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells. Cancer Res. 1999;59:2950-2956.
22. Peat N, Gendler SJ, Lalani N, et al. Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice. Cancer Res. 1992;52:1954-1960.
23. Segal-Eiras A, Croce MV. Breast cancer associated mucin: a review. Allergol Immunopathol (Madr). 1997;25:176-181.
24. Oosterkamp HM, Scheiner L, Stefanova MC, et al. Comparison of MUC-1 mucin expression in epithelial and non-epithelial cancer cell lines and demonstration of a new short variant form (MUC-1/Z). Intl J Cancer. 1997;72:87-94.
25. Hilkins J, Buijs F, Hingers J, et al. Monoclonal antibodies against milk fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer. 1984;34:197-206.
26. Devine PL, Warren JA, Ward BG, et al. The breast tumor-associated epitope defined by monoclonal antibody 3E1.2 is an O-linked mucin carbohydrate containing N-glycolyln euraminic acid. J Tumor Marker Oncol. 1990;5:11-26.
27. Burchell J, Gendler S, Taylor-Papadimitriou J. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. 1987;47:5476-5482.
28. Brossart P, Heinrich KS, Stuhler G, et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUCI tumor antigen for broadly applicable vaccine therapies. Blood. 1999;93:4309-4317.
29. Brossart P, Schneider A, Dill P, et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res. 2001;61:6846-6850.
30. Kirschenbaum A, Itkowitz SH, Wang JP, et al. MUC1 expression in prostate carcinoma: correlation with grade and stage. Mol Urol. 1999;3:163-168.
31. Ng YK, Pickens CI, Dang SM. Prognostic significance of increased immunodetectable MUC1 in prostate cancer. Proc Am Assoc Cancer Res. 1997;88:542.
32. Papadopoulos I, Sivridis E, Giatromanolaki A, et al. Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer. Clin Cancer Res. 2001;7:1533-1538.
33. Mastrangelo MJ, Maguire HC, Eisenlohr LC, et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 1995;6:409-422.
34. Gomella LG, Mastrangelo MJ, McCue PA, et al. Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol. 2001;166:1291-1295.
35. Buller RM, Smith GL, Cremer K, et al. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature. 1985;317:813-815.
36. Flexner C, Hugin A, Moss B. Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression. Nature. 1987; 330:259-262.
37. Jolly D. Viral vector systems for gene therapy. Cancer Gene Ther. 1994; 1:51-64.
38. Hwang C, Sanda MG. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy. Curr Opin Mol Ther. 1999;1: 471-479.
39. Rochlitz C, Figlin R, Squiban P, et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med. 2003;5:690-699.